spacer
home > white papers > Financial implications of off-site visits in clinical research, perception versus reality - Illingworth Research
WHITE PAPERS
logo_IllingwortE.jpg

Illingworth Research

phone +44 (0)1625617447
email info@illingworthreseach.com
web http://www.illingworthresearch.com
email Illingworth Research Ltd, Suite 5, Silk House, Park Green, Macclesfield, Cheshire, SK11 7QJ, England

Financial implications of off-site visits in clinical research, perception versus reality

The concept of patient centricity is still relatively new within clinical trials. For too long, the most important person in the trial has been overlooked… the patient. Here, we explore the benefits of conducting a more patient-centric trial for the patient, site and sponsor through mobile, or ‘off-site’ visits. These advantages are much greater than purely financial, although the financial implications of running a more patient-focused clinical trial may previously have deterred some from this approach. Home nursing in clinical trials continues to be thought of as a high value “premium” service, which many sponsors decline in an attempt to remain within budget for the trial. However, is the actual cost of off-site nursing more expensive than the traditional site model?
Financial implications of off-site visits in clinical research, perception versus reality
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Stevanato Group signs an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to provide pharma glass vials for 2 billion doses of COVID-19 vaccines under development


More info >>


White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>


Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement